Randomized controlled trials | Open trials | |
---|---|---|
Target sample sizes with statistical evidence | Agalsidase alfaa (26 patients) Canakinumaba (31 patients) Galsulfasea (39 patients) Agalsidase betaa (58 patients) Risedronatea (120 patients) Elosulfase alfaa (176 patients) Sunitinib b (191 patients) Tafamidisc (125 patients) Basiliximabc (376 patients) Dornase alphac (968 patients) | Cinacalceta (46 patients) Tamibarotene b (39 patients) Nilotinibb (282 patients) |
Feasibility | Idursulfasea (96 patients) Dasatinibb (150 patients) Eculizumabc (87 patients) | Phenylbutyratea (11 patients) Heminb (2 patients) Vorinostatb (6 patients) Cladribineb (9 patients) Freeze-dried concentrated human activated protein C c (3 patients) Metreleptin c (4 patients) Drying polyethylene glycol treatment human immunoglobulin c (7 patients) Infliximab c (Behcet’s disease) (12 patients) Tocilizumab c (Ewing sarcoma) (28 patients) |